Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918847 | 0.85 | PTGS2 (0.59) | PTGS2HMGCRALDH1A1CYP3A4PDE3B | |
| SCHEMBL918362 | 0.82 | HMGCR (0.44) | PTGS2HMGCRALDH1A1CYP3A4PDE3B | |
| Hydrochloric Acid SCHEMBL25186690 | 0.79 | HTR2A (0.61) | ALDH1A1CYP3A4HTR2AHTR2CHTR2B | |
| SCHEMBL6312974 | 0.79 | CALM1 (0.57) | PTGS2ALDH1A1CYP3A4HTR2AHTR2C | |
| SCHEMBL6931161 | 0.79 | PDE3B (0.41) | PTGS2HMGCRALDH1A1CYP3A4PDE3B | |
| SCHEMBL12844405 | 0.78 | ACHE (0.50) | PTGS2HMGCRALDH1A1CYP3A4PDE3B | |
| SCHEMBL8009626 | 0.78 | CYP1A2 (0.44) | HMGCRALDH1A1CYP3A4PDE3BPDE3A | |
| SCHEMBL6935944 | 0.77 | CYP1A2 (0.41) | HMGCRALDH1A1CYP3A4PDE3BPDE3A | |
| SCHEMBL6448298 | 0.77 | HMGCR (0.41) | PTGS2HMGCRALDH1A1CYP3A4PDE3B | |
| SCHEMBL7114104 | 0.77 | ALOX5 (0.53) | PTGS2HMGCRCYP3A4PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868047-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | WELICHEM BIOTECH INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| EP-1554236-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | Welichem Biotech Inc. (CA) | 2005-07-20 | — | — | EP | disclosed |
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2004031117-A1 | NOVEL BIOACTIVE DIPHENYL ETHENE COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS | WELICHEM BIOTECH INC. (CA) | 2004-04-15 | — | — | WO | disclosed |
| EP-1368306-A1 | NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES | Welichem Biotech Inc. (CA) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002057219-A1 | NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES | WELICHEM BIOTECH INC. (CA) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059733-A1 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | NFKBIA, IKBKB, IKBKE | PTGS2 293/4885HMGCR 2594/4885ALDH1A1 3063/4885 |
| US-20080139666-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues | LTK, MMP8, CHUK | PTGS2 512/4885HMGCR 1809/4885ALDH1A1 4482/4885 |
| US-20100094041-A1 | ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES | CHUK, MAP3K8, MAP3K1 | PTGS2 352/4885HMGCR 1870/4885ALDH1A1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.